CAPHA PHARMACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.000001 USD | -99.00% |
|
-.--% | -.--% |
Valuation
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 0.00007 | 0.008539 | 0.000853 | 0.008429 | 0.008187 | 0.008873 |
| Enterprise Value (EV) 1 | 0.3211 | 0.123 | 0.1743 | 0.284 | 0.3432 | 0.4239 |
| P/E ratio | -0 x | -0.07 x | -0.01 x | -0.12 x | -0.15 x | -0.12 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -1.28 x | -1.31 x | -2.51 x | -5.67 x | -8.66 x | -7.24 x |
| EV / FCF | -5.3 x | -0.54 x | -10.7 x | -4.33 x | -12.2 x | -10.4 x |
| FCF Yield | -18.9% | -187% | -9.36% | -23.1% | -8.22% | -9.65% |
| Price to Book | -0 x | -0.06 x | -0 x | -0.03 x | -0.02 x | -0.02 x |
| Nbr of stocks (in thousands) | 54,431 | 64,431 | 64,431 | 64,431 | 64,431 | 64,431 |
| Reference price 2 | 0.000001 | 0.000133 | 0.000013 | 0.000131 | 0.000127 | 0.000138 |
| Announcement Date | 4/30/18 | 4/29/19 | 4/29/20 | 4/29/21 | 4/29/22 | 4/26/23 |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | -0.2506 | -0.0938 | -0.0694 | -0.0501 | -0.0396 | -0.0585 |
| EBIT 1 | -0.2515 | -0.0951 | -0.0703 | -0.0507 | -0.04 | -0.0588 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -0.2675 | -0.123 | -0.0866 | -0.0686 | -0.0562 | -0.0759 |
| Net income 1 | -0.2675 | -0.123 | -0.0866 | -0.0686 | -0.0562 | -0.0759 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -0.004915 | -0.001918 | -0.001344 | -0.001065 | -0.000871 | -0.001178 |
| Free Cash Flow 1 | -0.0606 | -0.2297 | -0.0163 | -0.0656 | -0.0282 | -0.0409 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/30/18 | 4/29/19 | 4/29/20 | 4/29/21 | 4/29/22 | 4/26/23 |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 0.32 | 0.11 | 0.17 | 0.28 | 0.33 | 0.42 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | -1.281 x | -1.22 x | -2.498 x | -5.503 x | -8.457 x | -7.09 x |
| Free Cash Flow 1 | -0.06 | -0.23 | -0.02 | -0.07 | -0.03 | -0.04 |
| ROE (net income / shareholders' equity) | 69.7% | 37.4% | 47.2% | 26.3% | 17.4% | 19.5% |
| ROA (Net income/ Total Assets) | -49.6% | -18.8% | -883% | -756% | -690% | -1,101% |
| Assets 1 | 0.5391 | 0.6547 | 0.009808 | 0.009072 | 0.008141 | 0.006894 |
| Book Value Per Share 2 | -0.0100 | -0 | -0 | -0 | -0.0100 | -0.0100 |
| Cash Flow per Share 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capex 1 | 0 | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 4/30/18 | 4/29/19 | 4/29/20 | 4/29/21 | 4/29/22 | 4/26/23 |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 64 | |
| +31.36% | 588B | |
| -3.42% | 364B | |
| +18.02% | 326B | |
| +4.27% | 285B | |
| +14.69% | 239B | |
| +10.12% | 210B | |
| -7.12% | 200B | |
| +8.12% | 167B | |
| -1.42% | 161B |
- Stock Market
- Equities
- FPSUF Stock
- Financials Capha Pharmaceuticals Inc.